{"id":200401,"date":"2026-08-13T11:33:35","date_gmt":"2026-08-13T06:03:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=200401"},"modified":"2026-08-13T11:33:36","modified_gmt":"2026-08-13T06:03:36","slug":"granules-india-vs-shilpa-medicare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/granules-india-vs-shilpa-medicare\/","title":{"rendered":"Granules India vs Shilpa Medicare: Share Price, PE and ROE Compared"},"content":{"rendered":"
<\/div>\n

Granules India MCap Rs 21,437 Cr, PE 32.36x, ROE 11.70%. Shilpa Medicare MCap Rs 15,732 Cr, PE 52.92x, ROE 9.39%.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Granules India and Shilpa Medicare are both mid-cap pharma companies. Granules at Rs 21,437 Cr trades at PE 32.36x with ROE 11.70%. Shilpa at Rs 15,732 Cr is priced higher at PE 52.92x with lower ROE of 9.39%, reflecting market expectations for its oncology and injectables pipeline.<\/p>\n<\/div>\n

The Granules India vs Shilpa Medicare question comes up often among investors who follow the Pharmaceuticals space in India. Granules India MCap Rs 21,437 Cr, PE 32. 36x, ROE 11. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Granules India vs Shilpa Medicare as a research exercise.<\/p>\n

All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n